Reda E Girgis

Reda E Girgis


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
VMValentina Mercurio
Valentina Mercurio
MMMonica Mukherjee
Monica Mukherjee
RTRyan J. Tedford
Ryan J. Tedford
RZRoham T. Zamanian
Roham T. Zamanian
RKRubina M. Khair
Rubina M. Khair
PHPaul Hassoun
Paul Hassoun

21 April 2021 in Current Pulmonology Reports
Verified
Journal Article
Open access
PDF file
SKSheila Krishnan
Sheila Krishnan
EFErin M. Fricke
Erin M. Fricke
MCMarcos Cordoba
Marcos Cordoba
LCLaurie A. Chalifoux
Laurie A. Chalifoux
RGReda E Girgis
Reda E Girgis
Purpose of review: This study aims to describe the pathophysiology of pregnancy in pulmonary hypertension (PH) and review recent literature on maternal and fetal outcomes. Recent findings: There is an increasing number of pregnant women with PH. Maternal mortality in pulmonary arterial hypertension (PAH) ranges from 9 to 25%, most commonly from heart failure and arrythmias. The highest risk of death is peri-partum and post-partum. Fetal/neonatal morbidity and mortality are also substantial. There are high rates of prematurity, intrauterine growth retardation, and preeclampsia. Women should be referred to expert centers for management. Combination PAH therapy with parenteral prostacyclin and a phosphodiesterase type V inhibitor is recommended. Induced vaginal delivery is preferred, except in cases of severe heart failure or obstetric indications for cesarean section. Summary: Despite advances in management, pregnancy in PAH remains a high-risk condition and should be prevented.

21 October 2023 in Cells
Verified
Journal Article
Open access
PDF file
KUKatie Uhl
Katie Uhl
SPShreya Paithankar
Shreya Paithankar
DLDmitry Leshchiner
Dmitry Leshchiner
TJTara E. Jager
Tara E. Jager
MAMohamed Abdelgied
Mohamed Abdelgied
XLXiaopeng Li
Xiaopeng Li
Idiopathic pulmonary fibrosis (IPF) is a pathological condition wherein lung injury precipitates the deposition of scar tissue, ultimately leading to a decline in pulmonary function. Existing research indicates a notable exacerbation in the clinical prognosis of IPF patients following infection with COVID-19. This investigation employed bulk RNA-sequencing methodologies to describe the transcriptomic profiles of small airway cell cultures derived from IPF and post-COVID fibrosis patients. Differential gene expression analysis unveiled heightened activation of pathways associated with microtubule assembly and interferon signaling in IPF cell cultures. Conversely, post-COVID fibrosis cell cultures exhibited distinctive characteristics, including the upregulation of pathways linked to extracellular matrix remodeling, immune system response, and TGF-β1 signaling. Notably, BMP signaling levels were elevated in cell cultures derived from IPF patients compared to non-IPF control and post-COVID fibrosis samples. These findings underscore the molecular distinctions between IPF and post-COVID fibrosis, particularly in the context of signaling pathways associated with each condition. A better understanding of the underlying molecular mechanisms holds the promise of identifying potential therapeutic targets for future interventions in these diseases.

1 June 2023 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
MAMohamed Abdelgied
Mohamed Abdelgied
KUKatie Uhl
Katie Uhl
OCOliver G. Chen
Oliver G. Chen
CSChad Schultz
Chad Schultz
KTKaylie Tripp
Kaylie Tripp
XLXiaopeng Li
Xiaopeng Li
Idiopathic pulmonary fibrosis (IPF) is a pathological condition of unknown etiology that results from injury to the lung and an ensuing fibrotic response that leads to the thickening of the alveolar walls and obliteration of the alveolar space. The pathogenesis is not clear, and there are currently no effective therapies for IPF. Small airway disease and mucus accumulation are prominent features in IPF lungs, similar to cystic fibrosis lung disease. The ATP12A gene encodes the α-subunit of the nongastric H+, K+-ATPase, which functions to acidify the airway surface fluid and impairs mucociliary transport function in patients with cystic fibrosis. It is hypothesized that the ATP12A protein may play a role in the pathogenesis of IPF. The authors’ studies demonstrate that ATP12A protein is overexpressed in distal small airways from the lungs of patients with IPF compared with normal human lungs. In addition, overexpression of the ATP12A protein in mouse lungs worsened bleomycin induced experimental pulmonary fibrosis. This was prevented by a potassium competitive proton pump blocker, vonoprazan. These data support the concept that the ATP12A protein plays an important role in the pathogenesis of lung fibrosis. Inhibition of the ATP12A protein has potential as a novel therapeutic strategy in IPF treatment.

1 April 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MGMohamed A. Gashouta
Mohamed A. Gashouta
CMChristian A. Merlo
Christian A. Merlo
MPMatthew R. Pipeling
Matthew R. Pipeling
JMJohn F. McDyer
John F. McDyer
JHJ.W. Awori Hayanga
J.W. Awori Hayanga
RGReda E Girgis
Reda E Girgis

1 November 2005 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
OSOksana Anatolia Shlobin
Oksana Anatolia Shlobin
LDLesia K. Dropulic
Lesia K. Dropulic
JOJonathan B. Orens
Jonathan B. Orens
JMJohn F. Mcdyer
John F. Mcdyer
JCJohn V. Conte
John V. Conte
RGReda E Girgis
Reda E Girgis